Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management
Miriam Hobbs, DNP, APRN, CNP, Amie Fonder, PA-C, and Yi L. Hwa, DNP, APRN, CNP
From Mayo Clinic, Rochester, Minnesota
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Miriam Hobbs,DNP, CNP, APRN, 200 First Street SW, Rochester, MN 55905 E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2020;11(4):381–389 |
© 2020 Harborside™
Waldenström macroglobulinemia is a rare hematologic malignancy characterized by an IgM-associated lymphoplasmacytic lymphoma. Often, it is associated with an indolent disease course, and many patients are candidates for careful monitoring. As many patients present with advanced age and nonspecific constitutional symptoms, careful consideration should be given to treatment decisions, including when and how to treat for maximized clinical benefit with minimal toxicity. This article provides an evidence-based practical approach to appropriate monitoring of the asymptomatic patient and management of symptomatic patients who require treatment for this rare malignancy.
For access to the full length article, please sign in